Powder: -20°C for 3 years
In solvent: -80°C for 2 years
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
Description | TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others. |
Targets&IC50 | Fgr:<2.0 nM, c-Src:1.3 nM, CLK2:<2.0 nM, YES1:<2.0 nM, JAK3:1.2 nM |
Synonyms | TAK 901, Inhibitor, TAK-901, Aurora Kinase, TAK901, inhibit |
Molecular Weight | 504.65 |
Formula | C28H32N4O3S |
CAS No. | 934541-31-8 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Ethanol: <1 mg/mL
DMSO: 93 mg/mL (184.3 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.